Eleven-Year Survivor of Unresectable Intrahepatic Cholangiocarcinoma Treated Using Long-Term UFT Therapy

被引:0
作者
Takemura, Nobuyuki [1 ]
Kokudo, Norihiro [1 ]
Imamura, Hiroshi [1 ]
Takazawa, Yutaka [2 ]
Sano, Keiji [1 ]
Sugawara, Yasuhiko [1 ]
Nakagawa, Keiichi [3 ]
Ohtomo, Kuni [3 ]
Makuuchi, Masatoshi [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg,Artificial Organ & Transplantat Div, Hepatobiliary Pancreat Surg Div,Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Dept Pathol, Tokyo 1138655, Japan
[3] Univ Tokyo, Dept Radiol, Tokyo 1138655, Japan
关键词
Tegafur-uracil (UFT); Intrahepatic cholangiocarcinoma; Long-term survival; Chemotherapy;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade. In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT). The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection. The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head. A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy. The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter. External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter. Eleven years have now passed since the laparotomy, and the patient continues to lead a normal daily life working as a banker. The cumulative dose of UFT has reached 2511 g without any significant adverse effects. This case suggests that oral UFT might suppress the progression of ICC, contributing to this patient's 11-year survival period.
引用
收藏
页码:1997 / 1999
页数:3
相关论文
共 21 条
[1]  
[Anonymous], 1990, ANN SURG, V211, P277
[2]  
Asakura H, 2005, HEPATO-GASTROENTEROL, V52, P722
[3]  
FOUCAR E, 1979, GASTROENTEROLOGY, V77, P347
[4]   Report of the 16th follow-up survey of primary liver cancer [J].
Ikai, I ;
Arii, S ;
Ichida, T ;
Okita, K ;
Omata, M ;
Kojiro, M ;
Takayasu, K ;
Nakanuma, Y ;
Makuuchi, M ;
Matsuyama, Y ;
Yamaoka, Y .
HEPATOLOGY RESEARCH, 2005, 32 (03) :163-172
[5]   Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma [J].
Inoue, K ;
Makuuchi, M ;
Takayama, T ;
Torzilli, G ;
Yamamoto, J ;
Shimada, K ;
Kosuge, T ;
Yamasaki, S ;
Konishi, M ;
Kinoshita, T ;
Miyagawa, S ;
Kawasaki, S .
SURGERY, 2000, 127 (05) :498-505
[6]  
IZUMI R, 1995, AM J GASTROENTEROL, V90, P505
[7]   Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma [J].
Kawarada, Y ;
Yamagiwa, K ;
Das, BC .
AMERICAN JOURNAL OF SURGERY, 2002, 183 (06) :679-685
[8]   Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC) -: When is it worthwhile?: Single center experience with 27 resections in 50 patients over a 5-year period [J].
Lang, H ;
Sotiropoulos, GC ;
Frühauf, NR ;
Dömland, M ;
Paul, A ;
Kind, EM ;
Malagó, M ;
Broelsch, CE .
ANNALS OF SURGERY, 2005, 241 (01) :134-143
[9]   Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma [J].
Lee, MA ;
Woo, IS ;
Kang, JH ;
Hong, YS ;
Lee, KS .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (06) :346-350
[10]   Liver resection for hilar and peripheral cholangiocarcinomas: A study of 62 cases [J].
Madariaga, JR ;
Iwatsuki, S ;
Todo, S ;
Lee, RG ;
Irish, W ;
Starzl, TE .
ANNALS OF SURGERY, 1998, 227 (01) :70-79